Tack血管内系统在膝下动脉一期球囊扩张后夹层修复的12个月结果(TOBA II BTK)
TOBA II BTK是一项前瞻性、多中心、单臂研究,评估Tack血管内系统治疗膝下动脉球囊扩张后夹层的12个月安全性和有效性。共纳入233例Rutherford 3-5级缺血患者,所有患者均存在球囊扩张后夹层并接受Tack植入。12个月时无MALE+POD复合终点事件率为93.4%,Tack段通畅率81.3%,保肢率96.8%,免于CD-TLR率83.1%,AFS 89.3%。
要点
- Tack系统可有效修复膝下动脉球囊扩张后夹层,12个月通畅率81.3%、保肢率96.8%。
- 12个月免于MALE+POD复合终点事件率为93.4%,免于CD-TLR率为83.1%。
- 82.4%患者Rutherford分级持续改善,72.5%的指数创面愈合或改善。
核心结论
- Tack血管内系统治疗膝下动脉球囊扩张后夹层安全有效,12个月通畅率、保肢率和创面愈合率均较高。
研究设计与样本
- 前瞻性、多中心、单臂研究(TOBA II BTK,NCT02942966),纳入233例Rutherford 3-5级缺血患者,平均年龄74.4±10.0岁,157例男性。
- 病变特点:93.8%为原发病变,47.6%(118/248)为完全闭塞,平均靶病变长度80±49 mm,35.8%(89例)存在中重度钙化。
- 主要安全终点为30天MALE和围手术期全因死亡的复合终点,主要疗效终点为6个月MALE和30天POD的复合终点,12个月时评估观察性终点。
主要发现
- 所有患者均存在球囊扩张后夹层并接受至少1个Tack植入(范围1-16个),血管造影核心实验室判定341处夹层100%成功解决。
- 12个月时93.4%(170/182)患者免于MALE+POD复合终点,Tack段通畅率81.3%,保肢率96.8%,免于CD-TLR率83.1%,AFS 89.3%。
关键数值与推荐
- 12个月免于MALE+POD复合终点事件率93.4%(170/182)。
- 12个月Tack段通畅率81.3%,保肢率96.8%,免于CD-TLR率83.1%,AFS 89.3%。
- Rutherford分级持续改善率82.4%,改善≥3级者占62.4%(p<0.001)。
临床怎么用
- 对于膝下动脉球囊扩张后出现夹层的Rutherford 3-5级缺血患者,可考虑使用Tack血管内系统进行夹层修复。
- Tack系统植入后12个月通畅率和保肢率较高,可作为膝下动脉夹层修复的治疗选择之一。
局限性
- 本研究为单臂研究,缺乏随机对照,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To report the 12-month safety and efficacy outcomes of the investigational device exemption trial evaluating an implantable below-the-knee (BTK) dissection repair device. Materials and Methods: The prospective, multicenter, single-arm Tack-Optimized Balloon Angioplasty (TOBA) II BTK study (ClinicalTrials.gov identifier NCT02942966) evaluated the Tack Endovascular System in the BTK arteries vs objective performance goals derived from a systematic review of BTK angioplasty literature. Patients presenting with Rutherford category 3-5 ischemia were eligible and were enrolled during the procedure if angioplasty resulted in dissection(s) of the BTK arteries. Between February 2017 and December 2018, the study enrolled 233 patients (mean age 74.4±10.0 years; 157 men). Most lesions (93.8%) were de novo; almost half (118/248, 47.6%) were total occlusions. Mean target lesion length was 80±49 mm. Moderate to severe calcium was present in 89 (35.8%) lesions. The 30-day primary safety endpoint was a composite of major adverse limb events (MALE) and all-cause perioperative death (POD). The primary efficacy endpoint was a composite of MALE at 6 months and 30-day POD. These safety and efficacy endpoints were assessed at 12 months as observational endpoints along with amputation-free survival (AFS), freedom from clinically-driven target lesion revascularization (CD-TLR), vessel patency, and changes from baseline in clinical and quality of life measures. Results: All patients had post-PTA dissection and received at least 1 Tack implant (range 1 to 16). The angiographic core laboratory noted successful resolution of 100% of the 341 treated dissections. At 12 months, 93.4% (170/182) of patients remained free of the composite endpoint of MALE + POD. Tacked segment patency was 81.3% and limb salvage was 96.8% at 12 months; freedom from CD-TLR and AFS were 83.1% and 89.3%, respectively. Sustained Rutherford category improvement was reported in 82.4% of evaluated patients, with 62.4% improving ≥3 categories (p<0.001). Ninety of 124 index wounds (72.5%) healed or improved. Conclusion: The Tack Endovascular System is safe and effective in the treatment of post-angioplasty BTK dissections. Twelve-month outcome data from the TOBA II BTK study demonstrate high rates of patency, limb salvage, and wound healing.
引用
- Geraghty PJ, Adams GL, Schmidt A, et al. Twelve-Month Results of Tack-Optimized Balloon Angioplasty Using the Tack Endovascular System in Below-the-Knee Arteries (TOBA II BTK). J Endovasc Ther. 2020. PMID: 35156451. doi:10.1177/1526602820944402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。